Search Results - Merrick I. Ross

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Addendum: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial by Emily K. Ninmer, Hong Zhu, Kimberly A. Chianese-Bullock, Margaret von Mehren, Naomi B. Haas, Merrick I. Ross, Lynn T. Dengel, Craig L. Slingluff

    Published in Nature Communications (2025-09-01)
    Get full text
    Article


  2. 2

    Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial by Emily K. Ninmer, Hong Zhu, Kimberly A. Chianese-Bullock, Margaret von Mehren, Naomi B. Haas, Merrick I. Ross, Lynn T. Dengel, Craig L. Slingluff

    Published in Nature Communications (2024-03-01)
    Get full text
    Article


  3. 3

    Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma by Sydney A. Keatts, Aya F. Salem, David M. Swanson, Ahsan S. Farooqi, Andrew J. Bishop, Rodabe N. Amaria, Jennifer L. McQuade, Isabella C. Glitza Oliva, Adi Diab, Roi Weiser, Sarah B. Fisher, Ryan P. Goepfert, Merrick I. Ross, B. Ashleigh Guadagnolo, Devarati Mitra

    Get full text
    Article


  4. 4

    Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma by Merve Hasanov, Simin Kiany, Marie-Andrée Forget, Roland Bassett, Michael A. Davies, Adi Diab, Jeffrey E. Gershenwald, Isabella C. Glitza, Jeffrey E. Lee, Anthony Lucci, Jennifer L. McQuade, Sapna P. Patel, Merrick I. Ross, Hussein A. Tawbi, Jennifer A. Wargo, Michael K. Wong, Chantale Bernatchez, Patrick Hwu, Cara Haymaker, Rodabe N. Amaria

    Published in OncoImmunology (2025-12-01)
    Get full text
    Article


Search Tools: